

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) A pharmaceutical preparation ~~characterized by a content of~~ comprising at least one compound of general formula (I)



wherein R is a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents.

2. (Original) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R is a straight-chain C1-14 alkyl residue or a C3-14 cycloalkyl residue each.

3. (Currently amended) The pharmaceutical preparation according to claim 1 ~~or 2~~, in the compound of formula (I) wherein R is CH_3CH_2 , isopropyl, $\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$ or $\text{CH}_2(\text{CH}_2)_2\text{CH}_2\text{OH}$.

dithiocarbonato)palladium(II), Bis(O-butyl-dithiocarbonato)-palladium(II), Bis(O-hexyl-dithiocarbonato)palladium(II) or Bis(O-methyl-dithiocarbonato)palladium(II).

5. (Currently amended) The pharmaceutical preparation according to ~~any one of claims 1 to 4~~ claim 1, comprising additionally an immunosuppressive compound selected from the group consisting of cyclosporine, rapamycin, 15-deocyspergualine, OKT3 and azathioprine.

6. (Currently amended) The pharmaceutical preparation according to ~~any one of claims 1 to 6~~ claim 1, comprising additionally cytokines, interferon or further cytostatic agents.

7. (Currently amended) The pharmaceutical preparation according to ~~any one of claims 1 to 6~~ claim 1, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer or anti-autoimmunic agent.

8. (Currently amended) The pharmaceutical preparation according to ~~any one of claims 1 to 7~~ claim 1, further comprising a pharmaceutically compatible inert carrier or a diluent.

9. (Currently amended) ~~Use of A method for the treatment of cancerous disease comprising~~ a pharmaceutical preparation according to ~~any one of claims 1 to 8 for treating a cancerous disease~~ claim 1.

10. (Currently amended) ~~Use~~ The method according to claim 9, wherein the cancerous disease is the parvocellular bronchial carcinoma or colorectal carcinoma.

11. (Currently amended) ~~Use of~~ A method for the treatment of a cancerous disease comprising administering a pharmaceutical preparation according to ~~any one of claims 1 to 8 for treating an autoimmune disease~~ claim 1.

12. (Currently amended) A process for the production of a pharmaceutical preparation according to ~~any one of claims 1 to 8~~ claim 1, ~~characterized in that~~ wherein the compound according to formula (I) is mixed with a pharmaceutically compatible carrier or diluent.